Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

be impacted by government investigations, litigation and products liability claims.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opp
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
(Date:11/26/2014)... DE (PRWEB) November 26, 2014 ... Heroes recognition reception on December 5, 2014, in San ... meeting. The MPN Heroes event will honor clinicians, caregivers, ... field of myeloproliferative neoplasms (MPNs). , Special guest ... discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... , , SADDLE RIVER, N.J., July ... provider of sales and marketing support to U.S. pharmaceutical companies, ... results on Wednesday, August 5, 2009 after the market close. ... conference call beginning at 4:30 p.m. Eastern time on August 5, ...
... , , BRISBANE, Calif., July 29 ... it will release second quarter 2009 financial results on Thursday, August ... call and webcast will be hosted by InterMune at 4:30 p.m. ... access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ...
... , , , ... (Nasdaq: OSTE ), a leader in the emerging ... in a July 24, 2009 letter to the Company, the ... establishing restrictions on the importation and distribution of tissue products ...
Cached Biology Technology:PDI, Inc. to Hold Second Quarter 2009 Financial Results Conference Call on Wednesday, August 5, 2009 2InterMune to Release Second Quarter Financial Results on August 6 2Osteotech Resumes Shipments of Bulgarian Tissue 2Osteotech Resumes Shipments of Bulgarian Tissue 3
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... important for the survival of many types of cells ... cells that connect the cerebral cortex with the spinal ... amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). ... investigators from Massachusetts General Hospital (MGH) and the Harvard ...
... during the earliest phases of infection appears to depend ... called HLA Class I that have been inherited, as ... molecules display to the T lymphocytes that usually destroy ... issue of PLOS Medicine, researchers from the Partners AIDS ...
... packages for scientists eager to find natural substances to ... that is smaller than the proverbial gnat's eyelash. , ... technology, or NMR, scientists have unlocked secrets hidden in ... common two-stripe walking sticks, which are relatively harmless, plant-eating ...
Cached Biology News:Growth factor stimulates rapid extension of key motor neurons in brain 2Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3One-of-a-kind imaging probe reveals secrets useful for drug discovery 2One-of-a-kind imaging probe reveals secrets useful for drug discovery 3
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: